The CDE website shows Qilu Pharmaceutical applied for the marketing of nusinersen generic. Once controversial for high price, it treats SMA. Now many firms are involved, and SMA treatment progresses.
This article focuses on the challenges and opportunities for weight-loss drug development in 2025 after semaglutide and tirzepatide's market dominance. It covers GLP-1 drugs' potential in organ protection, new drug mechanisms, and pipeline products.
ADCs are a hot drug R&D area, with 16 global approvals and a >$10B 2023 market. Chinese firms shine, 2 products approved, 11 out-licensing deals in 2024, 5 over $1B, boosting ADC internationalization.
This article discusses magnesium stearate's role, drawbacks in tablet manufacturing, factors for choosing alternative lubricants, and lists some substitutes.
Explore how regenerative medicine and biotech are transforming drug development with stem cell therapies, personalised treatments, and innovative solutions.